Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • jake13
    Member
    • Aug 2013
    • 23

    cufflinks filter output gtf

    I have been running cufflinks on a number of RNA-seq files to find novel transcripts/isoforms. I sequenced fairly deeply and it seems to be calling a ton of novel, short, single exon transcripts, a number of which I think are junk. Do people usually filter these out before running cuffmerge and cuffcompare? Do you just write a small script to manually filter these?
    Thanks
  • chensy
    Junior Member
    • Aug 2013
    • 3

    #2
    I have the same question. waiting ...

    Comment

    • Wallysb01
      Senior Member
      • Feb 2011
      • 286

      #3
      Have you tried constraining your cufflinks assembly parameters? You could increase the -F and -j options (min-isoform-fraction and pre-mrna-fraction). But its been my general experience that if you’re looking for novel isoforms with just the cufflinks RABT assembly, you’re going to have to filter through a lot of junk no matter what you do with cufflinks.

      You can also start doing things a little more sophisticated with maker. They have nice way of handling cufflinks assemblies and potentially creating a “reannotation” with them. Check out: http://gmod.org/wiki/MAKER_Tutorial

      Another option is the PASA pipeline: http://pasa.sourceforge.net. Neither Maker or PASA may not really be easy to get up and running for the casual bioinformatic tool user but they aren’t that bad either.

      Comment

      • Darwin
        Member
        • Oct 2008
        • 16

        #4
        I generally only keep those of the new transcripts that have class_code "j". There might be something real in the other classes, but too many of them do not look like they're real.

        Concerning the -F and -j options: I tested those quite extensively but in my experience you just get more pre-mRNA in the transcripts.

        I have found that it matters how you filter your reads before aligning. If you have paired-end reads, only use the fragments where both reads map for building the transcripts.

        I have no experience with MAKER or PASA, but they look interesting. Thanks for the pointer.

        Comment

        • 11xinqi
          Member
          • Mar 2011
          • 31

          #5
          Originally posted by jake13 View Post
          I have been running cufflinks on a number of RNA-seq files to find novel transcripts/isoforms. I sequenced fairly deeply and it seems to be calling a ton of novel, short, single exon transcripts, a number of which I think are junk. Do people usually filter these out before running cuffmerge and cuffcompare? Do you just write a small script to manually filter these?
          Thanks
          Hi, do you have any idea about why cufflinks gives a large number of predicted transcripts and how to filter the result now? Thank you.

          Comment

          • N00bSeq
            Member
            • Mar 2014
            • 12

            #6
            Originally posted by 11xinqi View Post
            Hi, do you have any idea about why cufflinks gives a large number of predicted transcripts and how to filter the result now? Thank you.
            I don't really know why this happens (It does in my data as well. I suspect it is influenced by library construction method and any adapter and rRNA contamination that may be present.). But here is one way I have seen people dealing with it: http://www.ncbi.nlm.nih.gov/pubmed/23237380. Basically they look at the distributions of the "c" and "=" class codes, and based on the hypothesis that artifacts (an unknown subset of j,o,x,u etc) and partially assembled transcripts (c) have separate FPKM distributions (generally lower values) than perfectly assembled transcripts (=), they build a simple classifier that labels transcripts as artifacts if they have an FPKM lower than a certain threshold. The output GTF from cufflinks is then filtered using this threshold as a cutoff.

            This is another approach (FRFE), which according to the authors perform better with respect to single-exon transcripts: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882232/.

            If any of you know any other approaches, I am certainly interested in them.

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM
            • SEQadmin2
              Cancer Drug Resistance: The Lingering Barrier to Rising Survival
              by SEQadmin2



              Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

              There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
              07-08-2026, 05:17 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            31 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            23 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-20-2026, 11:10 AM
            0 responses
            214 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-13-2026, 10:26 AM
            0 responses
            79 views
            0 reactions
            Last Post SEQadmin2  
            Working...